vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company.

vTv Therapeutics Trading Up 2.4 %

Shares of VTVT opened at $21.70 on Friday. vTv Therapeutics has a 1 year low of $8.10 and a 1 year high of $30.99. The stock has a 50 day simple moving average of $15.23 and a 200-day simple moving average of $14.89. The stock has a market cap of $69.22 million, a PE ratio of -4.79 and a beta of 0.73.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC bought a new position in vTv Therapeutics in the 3rd quarter worth approximately $2,402,000. JPMorgan Chase & Co. bought a new position in vTv Therapeutics in the 4th quarter valued at $25,000. Finally, Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the period. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.